Emergent BioSolutions (EBS) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 136.2% versus a loss of 49.7%. Over five years, GLSI leads with a -41.8% price change compared with -88.6% for EBS. Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $259.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | GLSI |
|---|---|---|
| Share price | $5.05 | $19.25 |
| Market cap | $259.65M | $282.56M |
| 1-day change | -1.94% | -2.73% |
| YTD return | -59.14% | -8.38% |
| 1-year return | -49.70% | +136.20% |
| 5-year return | -88.58% | -41.84% |
| Forward P/E | 4.83 | — |
| EPS (TTM) | $-5.00 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $742.90M | — |
| Revenue growth (YoY) | -28.81% | — |
| Net income (latest FY) | $52.60M | $-19.36M |
| Gross margin | 56.09% | — |
| Operating margin | 13.47% | — |
| Net margin | 7.08% | — |
| 52-week high | $14.06 | $34.10 |
| 52-week low | $4.36 | $7.78 |
| Distance from 52-week high | -64.08% | -43.55% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.02% | +198.70% |
| Average volume | 1.11M | 160.76K |
| Shares outstanding | 51.42M | 14.68M |
| Employees | 900 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed EBS by 185.9 percentage points over the past year.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
EBS vs GLSI FAQ
Which is bigger, Emergent BioSolutions or Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $259.65M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or GLSI?
GLSI returned +136.20% over the past 12 months, compared with -49.70% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.